Wells Fargo & Company Cuts Integra LifeSciences (NASDAQ:IART) Price Target to $12.00

Integra LifeSciences (NASDAQ:IART) had its price objective decreased by Wells Fargo & Company from $13.00 to $12.00 in a report published on Friday,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the life sciences company’s stock.

A number of other research analysts have also weighed in on the stock. Citigroup dropped their price target on shares of Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating on the stock in a research report on Friday, October 31st. Wall Street Zen upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Integra LifeSciences in a research note on Monday, December 29th. Truist Financial reaffirmed a “hold” rating and issued a $13.00 target price (down from $15.00) on shares of Integra LifeSciences in a report on Monday, November 3rd. Finally, JPMorgan Chase & Co. lifted their price target on Integra LifeSciences from $12.00 to $13.00 and gave the stock an “underweight” rating in a report on Friday, October 31st. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Integra LifeSciences currently has an average rating of “Reduce” and an average target price of $14.80.

Integra LifeSciences Stock Performance

Shares of IART opened at $11.38 on Friday. The firm has a market capitalization of $886.39 million, a P/E ratio of -1.69 and a beta of 1.02. Integra LifeSciences has a 52 week low of $10.60 and a 52 week high of $24.36. The stock has a 50 day moving average price of $11.96 and a two-hundred day moving average price of $13.18. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.46 and a current ratio of 2.54.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Thursday, February 26th. The life sciences company reported $0.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.04. The company had revenue of $434.93 million for the quarter, compared to analysts’ expectations of $429.62 million. Integra LifeSciences had a positive return on equity of 14.76% and a negative net margin of 31.58%.Integra LifeSciences’s quarterly revenue was down 1.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.97 earnings per share. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. Equities analysts forecast that Integra LifeSciences will post 2.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Amalgamated Bank increased its holdings in Integra LifeSciences by 3.8% in the 3rd quarter. Amalgamated Bank now owns 19,809 shares of the life sciences company’s stock worth $284,000 after acquiring an additional 728 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in Integra LifeSciences by 6.4% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 14,200 shares of the life sciences company’s stock valued at $205,000 after purchasing an additional 848 shares during the last quarter. GAMMA Investing LLC boosted its position in Integra LifeSciences by 55.3% during the third quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock worth $37,000 after purchasing an additional 913 shares during the period. Osaic Holdings Inc. increased its stake in shares of Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after purchasing an additional 1,104 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of Integra LifeSciences by 8.0% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,159 shares of the life sciences company’s stock valued at $211,000 after purchasing an additional 1,278 shares during the period. Institutional investors own 84.78% of the company’s stock.

Key Headlines Impacting Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Q4 results: adjusted EPS of $0.83 topped consensus ($0.79) and revenue of $434.9M beat estimates — a near-term fundamental positive that likely supported buying. Integra Surprises With Q4 Sales
• Positive Sentiment: Management highlighted operational progress and a simplified operating model expected to deliver $25–$30M of savings in 2026, underpinning margin improvement expectations. Press Release (GlobeNewswire)
• Positive Sentiment: Core Codman Specialty Surgical segment showed organic growth (neurosurgery, ENT, instruments, strong international sales), offsetting weakness elsewhere and supporting recurring revenue quality. Segment Details
• Neutral Sentiment: Analyst/editor pieces highlight momentum metrics and style scores (useful for some investors) but are not new company-specific catalysts. Zacks Momentum Article
• Neutral Sentiment: Earnings call/transcripts and slide deck are available for deeper read — useful for investors who want management color on remediation, tariffs and execution. Earnings Call Transcript
• Negative Sentiment: Guidance mixed: FY-2026 adjusted EPS of $2.30–$2.40 and revenue guidance imply modest growth, but Q1 EPS guidance ($0.37–$0.45) is below consensus — a near-term headwind for sentiment. Guidance Details
• Negative Sentiment: Legacy issues: the company recorded a $511M goodwill impairment in 2025 and reported a GAAP net loss for the year; leverage remains elevated (net debt ~ $1.6B, ~4.5x leverage), which raises capital-allocation and downside risk concerns. Quiver / Results Summary
• Negative Sentiment: Analyst action: Wells Fargo lowered its price target from $13 to $12 and set an “equal weight” rating, which can cap near-term upside. Wells Fargo PT Cut (Benzinga)

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.